Brief: Nicox Announces Positive Post Hoc Results From NCX 4251 Phase 2b Mississippi Trial

Nicox SA

30/11/2021 06:38

Nov 30 (Reuters) - NICOX SA  NCOX.PA :
    * NICOX’S POSITIVE POST HOC RESULTS FROM NCX 4251 PHASE 2B
MISSISSIPPI TRIAL SUGGEST PATH FORWARD IN DRY EYE DISEASE
    * POTENTIAL ALTERNATIVE DEVELOPMENT PATH FOR DISCUSSION WITH
FDA
EARLY 2022
    * DRY EYE MARKET IS ESTIMATED TO BE WORTH OVER $5 BILLION
WORLDWIDE
    * A SUBGROUP OF PATIENTS IN PHASE 2B MISSISSIPPI CLINICAL
TRIAL
SHOWED GREATER RESPONSES TO NCX 4251 COMPARED TO PLACEBO IN
REDUCING THEIR DRY EYE SYMPTOMS

Source text for Eikon:  ID:nGNX9JW5Lh 
Further company coverage:  NCOX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))